Literature DB >> 33443063

A Novel Time-Activity Information-Sharing Approach Using Nonlinear Mixed Models for Patient-Specific Dosimetry with Reduced Imaging Time Points: Application in SPECT/CT After 177Lu-DOTATATE.

Theresa P Devasia1, Yuni K Dewaraja2, Kirk A Frey2, Ka Kit Wong2, Matthew J Schipper3.   

Abstract

Multiple-time-point SPECT/CT imaging for dosimetry is burdensome for patients and lacks statistical efficiency. A novel method for joint kidney time-activity estimation based on a statistical mixed model, a prior cohort of patients with complete time-activity data, and only 1 or 2 imaging points for new patients was compared with previously proposed single-time-point methods in virtual and clinical patient data.
Methods: Data were available for 10 patients with neuroendocrine tumors treated with 177Lu-DOTATATE and imaged up to 4 times between days 0 and 7 using SPECT/CT. Mixed models using 1 or 2 time points were evaluated retrospectively in the clinical cohort, using the multiple-time-point fit as the reference. Time-activity data for 250 virtual patients were generated using parameter values from the clinical cohort. Mixed models were fit using 1 (∼96 h) and 2 (4 h, ∼96 h) time points for each virtual patient combined with complete data for the other patients in each dataset. Time-integrated activities (TIAs) calculated from mixed model fits and other reduced-time-point methods were compared with known values.
Results: All mixed models and single-time-point methods performed well overall, achieving mean bias < 7% in the virtual cohort. Mixed models exhibited lower bias, greater precision, and substantially fewer outliers than did single-time-point methods. For clinical patients, 1- and 2-time-point mixed models resulted in more accurate TIA estimates for 94% (17/18) and 72% (13/18) of kidneys, respectively. In virtual patients, mixed models resulted in more than a 2-fold reduction in the proportion of kidneys with |bias| > 10% (6% vs. 15%).
Conclusion: Mixed models based on a historical cohort of patients with complete time-activity data and new patients with only 1 or 2 SPECT/CT scans demonstrate less bias on average and significantly fewer outliers when estimating kidney TIA, compared with popular reduced-time-point methods. Use of mixed models allows for reduction of the imaging burden while maintaining accuracy, which is crucial for clinical implementation of dosimetry-based treatment.
© 2021 by the Society of Nuclear Medicine and Molecular Imaging.

Entities:  

Keywords:  177Lu-DOTATATE; SPECT/CT; dosimetry; mixed model; radionuclide therapy

Mesh:

Substances:

Year:  2020        PMID: 33443063      PMCID: PMC8833869          DOI: 10.2967/jnumed.120.256255

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  20 in total

1.  MIRD Pamphlet No. 26: Joint EANM/MIRD Guidelines for Quantitative 177Lu SPECT Applied for Dosimetry of Radiopharmaceutical Therapy.

Authors:  Michael Ljungberg; Anna Celler; Mark W Konijnenberg; Keith F Eckerman; Yuni K Dewaraja; Katarina Sjögreen-Gleisner; Wesley E Bolch; A Bertrand Brill; Frederic Fahey; Darrell R Fisher; Robert Hobbs; Roger W Howell; Ruby F Meredith; George Sgouros; Pat Zanzonico; Klaus Bacher; Carlo Chiesa; Glenn Flux; Michael Lassmann; Lidia Strigari; Stephan Walrand
Journal:  J Nucl Med       Date:  2015-10-15       Impact factor: 10.057

2.  Uncertainty propagation for SPECT/CT-based renal dosimetry in (177)Lu peptide receptor radionuclide therapy.

Authors:  Johan Gustafsson; Gustav Brolin; Maurice Cox; Michael Ljungberg; Lena Johansson; Katarina Sjögreen Gleisner
Journal:  Phys Med Biol       Date:  2015-10-12       Impact factor: 3.609

3.  Dose Mapping After Endoradiotherapy with 177Lu-DOTATATE/DOTATOC by a Single Measurement After 4 Days.

Authors:  Heribert Hänscheid; Constantin Lapa; Andreas K Buck; Michael Lassmann; Rudolf A Werner
Journal:  J Nucl Med       Date:  2017-06-06       Impact factor: 10.057

4.  Technical Note: Single time point dose estimate for exponential clearance.

Authors:  Mark T Madsen; Yusuf Menda; Thomas M O'Dorisio; M Sue O'Dorisio
Journal:  Med Phys       Date:  2018-04-16       Impact factor: 4.071

5.  Kidney dosimetry during 177Lu-DOTATATE therapy in patients with neuroendocrine tumors: aspects on calculation and tolerance.

Authors:  Mattias Sandström; Ulrike Garske-Román; Silvia Johansson; Dan Granberg; Anders Sundin; Nanette Freedman
Journal:  Acta Oncol       Date:  2017-09-18       Impact factor: 4.089

6.  Accuracy and optimal timing of activity measurements in estimating the absorbed dose of radioiodine in the treatment of Graves' disease.

Authors:  S Merrill; J Horowitz; A C Traino; S R Chipkin; C V Hollot; Y Chait
Journal:  Phys Med Biol       Date:  2011-01-06       Impact factor: 3.609

7.  Individualised 177Lu-DOTATATE treatment of neuroendocrine tumours based on kidney dosimetry.

Authors:  Anna Sundlöv; Katarina Sjögreen-Gleisner; Johanna Svensson; Michael Ljungberg; Tomas Olsson; Peter Bernhardt; Jan Tennvall
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-03-22       Impact factor: 9.236

8.  Influence of sampling schedules on [177Lu]Lu-PSMA dosimetry.

Authors:  Andreas Rinscheid; Peter Kletting; Matthias Eiber; Ambros J Beer; Gerhard Glatting
Journal:  EJNMMI Phys       Date:  2020-06-17

9.  Feasibility of simplifying renal dosimetry in 177Lu peptide receptor radionuclide therapy.

Authors:  Anna Sundlöv; Johan Gustafsson; Gustav Brolin; Nadja Mortensen; Rebecca Hermann; Peter Bernhardt; Johanna Svensson; Michael Ljungberg; Jan Tennvall; Katarina Sjögreen Gleisner
Journal:  EJNMMI Phys       Date:  2018-07-05

10.  Feasibility and accuracy of single time point imaging for renal dosimetry following 177Lu-DOTATATE ('Lutate') therapy.

Authors:  Kathy P Willowson; Enid Eslick; Hyunju Ryu; Aurora Poon; Elizabeth J Bernard; Dale L Bailey
Journal:  EJNMMI Phys       Date:  2018-12-20
View more
  3 in total

Review 1.  Neuroendocrine Tumors and Peptide Receptor Radionuclide Therapy: When Is the Right Time?

Authors:  Thomas A Hope; Marianne Pavel; Emily K Bergsland
Journal:  J Clin Oncol       Date:  2022-06-01       Impact factor: 50.717

2.  Patient-specific dosimetry adapted to variable number of SPECT/CT time-points per cycle for [Formula: see text]Lu-DOTATATE therapy.

Authors:  Laure Vergnaud; Anne-Laure Giraudet; Aurélie Moreau; Julien Salvadori; Alessio Imperiale; Thomas Baudier; Jean-Noël Badel; David Sarrut
Journal:  EJNMMI Phys       Date:  2022-05-16

3.  EANM dosimetry committee recommendations for dosimetry of 177Lu-labelled somatostatin-receptor- and PSMA-targeting ligands.

Authors:  Katarina Sjögreen Gleisner; Nicolas Chouin; Pablo Minguez Gabina; Francesco Cicone; Silvano Gnesin; Caroline Stokke; Mark Konijnenberg; Marta Cremonesi; Frederik A Verburg; Peter Bernhardt; Uta Eberlein; Jonathan Gear
Journal:  Eur J Nucl Med Mol Imaging       Date:  2022-03-14       Impact factor: 10.057

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.